Biocon’s stock extended its upward trajectory for a second consecutive session after the company posted stronger-than-anticipated quarterly performance. The update encouraged several brokerage firms to revise target prices upward, citing better cost controls and improving visibility across key product lines. Shares have now advanced nearly 10 percent in two days as trading activity remained elevated. Investor confidence strengthened further as management reiterated expectations around pipeline progress and market expansion priorities.